AilseBio
The startup develops immuno-oncology vaccines that utilize a proprietary platform to identify cancer-specific antigens encoded in abnormal RNAs, which are overlooked by current detection methods. This technology enhances cellular immunity, providing targeted treatment options for various types of cancer.
- Biotechnology
Updated 7 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops immuno-oncology vaccines that utilize a proprietary platform to identify cancer-specific antigens encoded in abnormal RNAs, which are overlooked by current detection methods. This technology enhances cellular immunity, providing targeted treatment options for various types of cancer.